Table 2.
Base-case results
| SoC | PEM | Incremental PEM vs. SoC | |
|---|---|---|---|
| Life-years | 2.05 | 3.35 | 1.31 |
| Expected time in progression free state (years) | 0.55 | 2.16 | 1.62 |
| Expected time in progressive state (years) | 1.50 | 1.19 | −0.31 |
| QALYs | 1.55 | 2.60 | 1.05 |
| Costs ($US) | 260,223 | 362,662 | 102,439 |
| Drug acquisition cost | 25,090 | 120,478 | 95,388 |
| Pre-medication cost | 328 | 0 | −328 |
| Drug administration cost | 1683 | 3854 | 2171 |
| Disease management cost | 173,227 | 198,458 | 25,231 |
| Post-discontinuation therapy cost | 27,989 | 11,084 | −16,905 |
| Terminal care cost | 29,573 | 28,268 | −1305 |
| Adverse event cost | 2334 | 521 | −1813 |
| Incremental cost-effectiveness ratio ($US) | |||
| Cost per life-year gained | 78,344 | ||
| Cost per QALY gained | 97,621 | ||
PEM pembrolizumab, QALY quality-adjusted life-year, SoC standard-of-care